We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+7.34%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$14.8B
AUM Growth
+$2.13B
(+17%)
Cap. Flow
+$1.52B
Cap. Flow
% of AUM
10.28%
Top 10 Holdings %
Top 10 Hldgs %
17.14%
Holding
1,089
New
119
Increased
321
Reduced
473
Closed
155
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$132M |
| 2 |
Apple
AAPL
|
+$117M |
| 3 |
Microsoft
MSFT
|
+$100M |
| 4 |
Fidelity National Information Services
FIS
|
+$94.3M |
| 5 |
FedEx
FDX
|
+$91.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$97.2M |
| 2 |
Booking.com
BKNG
|
+$94.2M |
| 3 |
Phillips 66
PSX
|
+$82.9M |
| 4 |
Gilead Sciences
GILD
|
+$73.9M |
| 5 |
Snowflake
SNOW
|
+$51.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.09% |
| 2 | Financials | 15.5% |
| 3 | Healthcare | 14.12% |
| 4 | Consumer Discretionary | 11.36% |
| 5 | Industrials | 9.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
926
Mistras Group
MG
$490M
| $89.9K | ﹤0.01% |
18,227
-38,506
| -68% | -$174K |
|
927
Q32 Bio
QTTB
$467M
| $89.8K | ﹤0.01% |
3,959
-545
| -12% | -$14.5K |
|
|
TUP
928
DELISTED
Tupperware Brands Corporation
TUP
| $85.4K | ﹤0.01% |
20,629
-116,683
| -85% | -$626K |
|
929
Daktronics
DAKT
$953M
| $83.1K | ﹤0.01% |
29,459
-411,811
| -93% | -$1.27M |
|
930
Allogene Therapeutics
ALLO
$573M
| $70.6K | ﹤0.01% |
11,217
-524,151
| -98% | -$4.85M |
|
931
Neuropace
NPCE
$522M
| $35.3K | ﹤0.01% |
+23,692
| New | +$52.6K |
|
|
JNCE
932
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $32K | ﹤0.01% |
28,791
-1,559
| -5% | -$2.22K |
|
|
AXDX
933
DELISTED
Accelerate Diagnostics
AXDX
| $23.4K | ﹤0.01% |
3,308
-7,390
| -69% | -$80.7K |
|
934
National CineMedia
NCMI
$371M
| $8.09K | ﹤0.01% |
+3,678
| New | +$16.2K |
|
935
Arbutus Biopharma
ABUS
$871M
| – | – |
-183,867
| Closed | -$351K |
|
936
Acco Brands
ACCO
$401M
| – | – |
-437,094
| Closed | -$2.14M |
|
937
Albertsons Companies
ACI
$5.67B
| – | – |
-1,204,311
| Closed | -$29.9M |
|
938
Adtran
ADTN
$730M
| – | – |
-638,205
| Closed | -$12.5M |
|
|
ADVM
939
DELISTED
Adverum Biotechnologies
ADVM
| – | – |
-55,621
| Closed | -$528K |
|
940
AAR Corp
AIR
$5.62B
| – | – |
-19,869
| Closed | -$712K |
|
941
Arhaus
ARHS
$1.12B
| – | – |
-30,080
| Closed | -$212K |
|
942
Asana
ASAN
$1.89B
| – | – |
-14,317
| Closed | -$318K |
|
943
Aurinia Pharmaceuticals
AUPH
$1.92B
| – | – |
-35,484
| Closed | -$267K |
|
|
AZEK
944
DELISTED
The AZEK Co
AZEK
| – | – |
-42,564
| Closed | -$707K |
|
|
BHR
945
Braemar Hotels & Resorts
BHR
$160M
| – | – |
-475,032
| Closed | -$2.04M |
|
946
BellRing Brands
BRBR
$1.59B
| – | – |
-13,136
| Closed | -$271K |
|
|
BRDG
947
DELISTED
Bridge Investment Group
BRDG
| – | – |
-19,085
| Closed | -$277K |
|
948
Braze
BRZE
$2.83B
| – | – |
-24,372
| Closed | -$849K |
|
949
Peabody Energy
BTU
$2.83B
| – | – |
-196,633
| Closed | -$4.88M |
|
950
Beazer Homes USA
BZH
$913M
| – | – |
-276,244
| Closed | -$2.67M |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q4 2022 Portfolio in Review
As of Q4 2022, Jacobs Levy Equity Management held 1,089 positions worth $14.8B, up 17% from $12.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Jacobs Levy Equity Management deployed $1.52B of net new capital in Q4 2022, opening 119 new positions and adding to 321 existing holdings. Its largest new stake was Fidelity National Information Services: 1,326,663 shares worth $90M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Booking.com, an estimated $94.2M trimmed.
- Jacobs Levy Equity Management's largest Q4 2022 buy was Fidelity National Information Services: 1,326,663 shares worth $90M.
- Jacobs Levy Equity Management added most to Vertex Pharmaceuticals in Q4 2022, an estimated $132M increase.
- Jacobs Levy Equity Management's biggest Q4 2022 reduction was Booking.com, cutting an estimated $94.2M.
- Jacobs Levy Equity Management fully exited Cigna in Q4 2022, selling an estimated $97.2M.
- Jacobs Levy Equity Management's ten largest holdings make up 17% of its $14.8B portfolio in Q4 2022.
- Jacobs Levy Equity Management opened 119 new positions and closed 155 in Q4 2022.
- Jacobs Levy Equity Management's portfolio value rose 17% quarter-over-quarter to $14.8B.
Based on Jacobs Levy Equity Management's 13F filing for Q4 2022, filed 14 Feb 2023.